| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $542K | — |
| Cost of Revenue | $448K | — |
| R&D Expense | $3.4M | +5.0% |
| SG&A Expense | $5.6M | -11.2% |
| Operating Income | -$8.9M | +6.7% |
| Net Income | -$23.1M | +35.1% |
| EPS (Basic) | -$0.08 | +60.0% |
| EPS (Diluted) | -$0.08 | +60.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $0 | -100.0% |
| Accounts Receivable | $287K | — |
| Inventory | $1.4M | +470.8% |
| Current Assets | $2.1M | +63.0% |
| Total Assets | $2.2M | +59.6% |
| Current Liabilities | $157.7M | +17.8% |
| Total Liabilities | $157.7M | +17.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$6.6M | -21.9% |
| Capital Expenditures | $2K | -63.4% |
| Investing Cash Flow | -$2K | +63.4% |
| Financing Cash Flow | $6.3M | +11.2% |
| Free Cash Flow | -$6.6M | -21.8% |
| Stockholders' Equity |
| -$184.5M |
| -15.9% |